Trial reportDiabetic medicine : a journal of the British Diabetic Association2026
Cost-effectiveness of the diabetes remission clinical trial (DiRECT)/Counterweight-Plus weight management programme, based on 5-year follow-up.
Trial report in Diabetic medicine : a journal of the British Diabetic Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
aimsFollow-up of the Counterweight-Plus intervention in DiRECT has demonstrated 6.1 kg weight loss and 10 % remissions from type 2 diabetes at 5 years. We previously reported cost-effectiveness based on 2-year results. We now present an updated cost-effectiveness analysis, based on available 5-year data.
methodsA lifetime cost-effectiveness analysis was conducted using the 5-year data from DiRECT, including time to relapse from remission from type 2 diabetes, intervention costs (practitioner appointment visits, low-energy formula diet sachets), routine healthcare resource use (primary, secondary, and tertiary care contacts), medications (anti-hypertensive and anti-diabetic medicines), and quality of life (EuroQol EQ-5D-3L). Modelling assumed that all those in remission at 5 years would relapse after a maximum of 10 years.
resultsTotal (discounted) healthcare cost-savings (excluding intervention costs) per participant over 5 years amounted to £2091. On average, healthcare costs per annum were ~£480 per participant lower in the intervention arm (p < 0.05). Intervention resource use beyond 2 years added relatively little to the total intervention cost (set-up, formula diet and practice visits), which amounted to £1691 (95% CI: £1566, 1822) per participant over 5 years. Reduced hospital admissions accounted for the major part of this saving, with the remainder being across primary and secondary care, and anti-diabetic and anti-hypertensive medications. Remission in DiRECT was associated with a significant improvement in quality of life, and the intervention arm was modelled to achieve both cost-savings of ~£400 and quality adjusted life year gains of 0.043 over 5 years, with further benefits due to reduced mortality in remission. Over the full lifetime horizon of the analysis the intervention was modelled to produce 0.08 incremental QALYs, saving £496 per participant.
conclusionsThe costs involved in achieving remissions from type 2 diabetes with the Counterweight-Plus diet programme were offset within 5 years through reduced healthcare resource use. Though remission may ultimately relapse, sustained weight loss brings other longer term health gains. The intervention, even using one-to-one face-to-face contacts rather than remote delivery, which is increasingly adopted, generated both health gains and cost-savings compared with current best practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.